A corporation with over 100 years of history and multibillion dollar assets under management has a venture arm that invests in healthcare. The venture arm will be contributing to investments in biotech companies in Series A and later stage companies. The goal of this venture arm is to bring new biotech innovation to Saudi Arabia and the Middle Eastern regions. Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms.
Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines.
The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment